Effect of eye pigmentation on transscleral drug delivery.

Ocular drug delivery. AAPS J (2010) 2.19

Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids. Drug Metab Dispos (2011) 1.48

Recent advances in ophthalmic drug delivery. Ther Deliv (2010) 1.31

Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis (2008) 1.15

Retracted Influence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerve. J Pharmacol Exp Ther (2009) 1.14

Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res (2013) 1.06

Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. Invest Ophthalmol Vis Sci (2009) 1.00

Retracted Sclera-choroid-RPE transport of eight β-blockers in human, bovine, porcine, rabbit, and rat models. Invest Ophthalmol Vis Sci (2011) 1.00

Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest Ophthalmol Vis Sci (2008) 0.98

Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes. Expert Opin Drug Deliv (2010) 0.94

Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes. Exp Eye Res (2012) 0.92

Fluorogenic affinity label for the facile, rapid imaging of proteins in live cells. Org Biomol Chem (2009) 0.89

Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide. Int J Pharm (2012) 0.81

In vitro transport and partitioning of AL-4940, active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the posterior segment. J Ocul Pharmacol Ther (2010) 0.79

Intraocular safety and pharmacokinetics of hexadecyloxypropyl-cidofovir (HDP-CDV) as a long-lasting intravitreal antiviral drug. Invest Ophthalmol Vis Sci (2011) 0.78

Transporter-targeted lipid prodrugs of cyclic cidofovir: a potential approach for the treatment of cytomegalovirus retinitis. J Pharm Sci (2012) 0.78

Recent patents on ophthalmic nanoformulations and therapeutic implications. Recent Pat Drug Deliv Formul (2014) 0.77

Retracted Hydrophilic prodrug approach for reduced pigment binding and enhanced transscleral retinal delivery of celecoxib. Mol Pharm (2012) 0.76

The effect of ocular pigmentation on transscleral delivery of triamcinolone acetonide. J Ocul Pharmacol Ther (2013) 0.75

Pharmacokinetics of heroin and its metabolites in vitreous humor and blood in a living pig model. Forensic Toxicol (2016) 0.75

Progressive retinal detachment secondary to juxtapapillary microholes in association with type 3 posterior staphylomas. Clin Ophthalmol (2014) 0.75

Pharmacokinetics and efficacy of intraocular flurbiprofen. Graefes Arch Clin Exp Ophthalmol (2017) 0.75

Retinopathy following chloroquine therapy. Lancet (1959) 4.81

The physical and chemical properties of eumelanin. Pigment Cell Res (2006) 2.53

Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci (2006) 1.52

Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci (2000) 1.43

Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev (2001) 1.32

Periocular routes for retinal drug delivery. Expert Opin Drug Deliv (2004) 1.31

Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol (2005) 1.30

Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci (2003) 1.29

Drug delivery to the posterior segment from drops. Surv Ophthalmol (2002) 1.24

Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer. Invest Ophthalmol Vis Sci (2006) 1.18

Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology (2005) 1.16

Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res (2004) 1.15

High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol (1999) 1.12

Binding of drugs to eye melanin is not predictive of ocular toxicity. Regul Toxicol Pharmacol (1998) 1.12

Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci (2000) 1.10

THE OCULAR UPTAKE OF SUBCONJUNCTIVALLY INJECTED C14 HYDROCORTISONE. 1. TIME AND MAJOR ROUTE OF PENETRATION IN A NORMAL EYE. Am J Ophthalmol (1964) 1.02

Intraocular distribution of 70-kDa dextran after subconjunctival injection in mice. Invest Ophthalmol Vis Sci (2002) 1.01

Quantitative determination of the melanin contents in ocular tissues from human blue and brown eyes. J Ocul Pharmacol (1992) 1.00

Correlation between rod photoreceptor numbers and levels of ocular pigmentation. Invest Ophthalmol Vis Sci (2002) 0.99

Transscleral drug delivery to the retina and choroid. Prog Retin Eye Res (2002) 0.97

Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab Dispos (2002) 0.93

Probing the building blocks of eumelanins using scanning electron microscopy. Pigment Cell Res (2000) 0.91

Regional differences in ocular concentration of gentamicin after subconjunctival and retrobulbar injection in the rabbit. Am J Ophthalmol (1977) 0.90

Intraocular tissue plasminogen activator concentrations after subconjunctival delivery. Ophthalmology (1993) 0.88

Relevance of drug-melanin interactions to ocular pharmacology and toxicology. J Ocul Pharmacol (1994) 0.86

Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. Invest Ophthalmol Vis Sci (1996) 0.86

Binding characteristics of fluoroquinolones to synthetic levodopa melanin. J Pharm Pharmacol (2003) 0.85

Intraocular penetration kinetics of prednisolone after subconjunctival injection in rabbits. Ophthalmic Res (1988) 0.84

Binding of the beta-blockers timolol and H 216/44 to ocular melanin. Exp Eye Res (1988) 0.84

Formulation effects on ocular absorption of brimonidine in rabbit eyes. J Ocul Pharmacol Ther (2002) 0.84

Intraocular penetration of ketoconazole in rabbits. Cornea (1992) 0.83

Comparative intraocular penetration of topical and injected cefuroxime. Br J Ophthalmol (1996) 0.83

Significance of melanin binding and metabolism in the activity of 5-acetoxyacetylimino-4-methyl-delta2-1,3,4,-thiadiazolin e-2-sulfonamide. Eur J Pharm Biopharm (1998) 0.83

Topical delivery system of ophthalmic drugs by periocular injection with viscous solution. Biol Pharm Bull (1999) 0.82

Drug absorption behavior after periocular injections. Biol Pharm Bull (1999) 0.82

2nd Ophthalmic Drug Development and Delivery Summit. Expert Opin Drug Deliv (2007) 0.81

Absorption, distribution and excretion of 14C-chloroquine after single oral administration in albino and pigmented rats: binding characteristics of chloroquine-related radioactivity to melanin in-vivo. J Pharm Pharmacol (2003) 0.80

Concentration of gentamicin in experimental corneal ulcers. Topical vs subconjunctival therapy. Arch Ophthalmol (1974) 0.80

Non-systemic delivery of topical brimonidine to the brain: a neuro-ocular tissue distribution study. J Drug Target (2006) 0.79

Tolerability, kinetics, and efficacy of subconjunctival pefloxacin in pigmented rabbits. Antimicrob Agents Chemother (1995) 0.78

Concern Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol (2011) 1.69

Intravitreal Poly(L-lactide) Microparticles Sustain Retinal and Choroidal Delivery of TG-0054, a Hydrophilic Drug Intended for Neovascular Diseases. Drug Deliv Transl Res (2011) 1.58

Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ACS Nano (2012) 1.56

Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci (2006) 1.52

Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids. Drug Metab Dispos (2011) 1.48

Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res (2008) 1.36

Periocular routes for retinal drug delivery. Expert Opin Drug Deliv (2004) 1.31

Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol (2005) 1.30

Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol (2005) 1.28

Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci (2007) 1.25

Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol (2003) 1.19

Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer. Invest Ophthalmol Vis Sci (2006) 1.18

Development and in-vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur. J Control Release (2002) 1.17

Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci (2010) 1.17

Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res (2004) 1.15

Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR). Invest Ophthalmol Vis Sci (2010) 1.15

Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis (2008) 1.15

Retracted Influence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerve. J Pharmacol Exp Ther (2009) 1.14

A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm Res (2002) 1.10

Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes (2009) 1.08

Pluronic F127 gel formulations of deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle. J Control Release (2002) 1.06

Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res (2013) 1.06

Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch Ophthalmol (2009) 1.05

Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res (2008) 1.05

Acidic nanoparticles are trafficked to lysosomes and restore an acidic lysosomal pH and degradative function to compromised ARPE-19 cells. PLoS One (2012) 1.05

Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond) (2010) 1.04

Rescue of photoreceptor degeneration by curcumin in transgenic rats with P23H rhodopsin mutation. PLoS One (2011) 1.01

Preparation of budesonide and budesonide-PLA microparticles using supercritical fluid precipitation technology. AAPS PharmSciTech (2002) 1.01

Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. Invest Ophthalmol Vis Sci (2009) 1.00

Retracted Sclera-choroid-RPE transport of eight β-blockers in human, bovine, porcine, rabbit, and rat models. Invest Ophthalmol Vis Sci (2011) 1.00

Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest Ophthalmol Vis Sci (2008) 0.98

Induction of vascular endothelial growth factor by 4-hydroxynonenal and its prevention by glutathione precursors in retinal pigment epithelial cells. Eur J Pharmacol (2002) 0.95

Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. Eur J Pharmacol (2004) 0.94

Cassette analysis of eight beta-blockers in bovine eye sclera, choroid-RPE, retina, and vitreous by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.94

Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1). Eur J Pharmacol (2002) 0.93

Drug and gene delivery to the back of the eye: from bench to bedside. Invest Ophthalmol Vis Sci (2014) 0.93

Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes. Exp Eye Res (2012) 0.92

Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis (2007) 0.92

Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res (2009) 0.92

Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-alpha-induced angiogenesis in chick chorioallantoic membrane (CAM). J Ocul Pharmacol Ther (2009) 0.91

Suprachoroidal delivery in a rabbit ex vivo eye model: influence of drug properties, regional differences in delivery, and comparison with intravitreal and intracameral routes. Mol Vis (2013) 0.91

Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs. Nanomedicine (2011) 0.91

Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano (2013) 0.91

Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol (2013) 0.90

Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J Ocul Pharmacol Ther (2011) 0.89

Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process. Pharm Res (2004) 0.89

Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium. FASEB J (2009) 0.88

Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. J Pharm Pharmacol (2003) 0.88

Comparison of suprachoroidal drug delivery with subconjunctival and intravitreal routes using noninvasive fluorophotometry. PLoS One (2012) 0.88

Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization. Invest Ophthalmol Vis Sci (2012) 0.88

Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model. Nanomedicine (Lond) (2011) 0.87

Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin. Invest Ophthalmol Vis Sci (2010) 0.86

Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism. J Pharmacol Exp Ther (2007) 0.86

Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology (2012) 0.86

Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab. Mol Pharm (2013) 0.86

Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone. Invest Ophthalmol Vis Sci (2012) 0.85

Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor. Invest Ophthalmol Vis Sci (2011) 0.85

Effect of diabetes on transscleral delivery of celecoxib. Pharm Res (2008) 0.83

Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol Cancer Ther (2009) 0.83

Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow. Drug Metab Dispos (2011) 0.82

Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance. Drug Metab Dispos (2012) 0.82

Preparation of budesonide- and indomethacin-hydroxypropyl-beta-cyclodextrin (HPBCD) complexes using a single-step, organic-solvent-free supercritical fluid process. Eur J Pharm Sci (2004) 0.82

Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide. Int J Pharm (2012) 0.81

Withaferin A effectively targets soluble vimentin in the glaucoma filtration surgical model of fibrosis. PLoS One (2013) 0.81

Evidence for LHRH-receptor expression in human airway epithelial (Calu-3) cells and its role in the transport of an LHRH agonist. Pharm Res (2004) 0.81

Transport of deslorelin, an LHRH agonist, is vectorial and exhibits regional variation in excised bovine nasal tissue. J Pharm Pharmacol (2004) 0.81

AQ4, an antitumor anthracenedione, inhibits endothelial cell proliferation and vascular endothelial growth factor secretion: implications for the therapy of ocular neovascular disorders. Eur J Pharmacol (2007) 0.81

Silibinin, dexamethasone, and doxycycline as potential therapeutic agents for treating vesicant-inflicted ocular injuries. Toxicol Appl Pharmacol (2012) 0.81

2nd Ophthalmic Drug Development and Delivery Summit. Expert Opin Drug Deliv (2007) 0.81

Retracted Self-assembled phenylalanine-α,β-dehydrophenylalanine nanotubes for sustained intravitreal delivery of a multi-targeted tyrosine kinase inhibitor. J Control Release (2013) 0.81

Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts. J Ocul Pharmacol Ther (2007) 0.81

Human scleral diffusion of anticancer drugs from solution and nanoparticle formulation. Pharm Res (2009) 0.81

The safety of intraocular ketorolac in rabbits. Invest Ophthalmol Vis Sci (2006) 0.80

Polychromatic angiography for the assessment of VEGF-induced BRB dysfunction in the rabbit retina. Invest Ophthalmol Vis Sci (2013) 0.80

Ophthalmic light sensitive nanocarrier systems. Drug Discov Today (2008) 0.80

Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab. Mol Pharm (2013) 0.80

Pirfenidone nanoparticles improve corneal wound healing and prevent scarring following alkali burn. PLoS One (2013) 0.80

Retracted Immunohistochemical and functional characterization of peptide, organic cation, neutral and basic amino acid, and monocarboxylate drug transporters in human ocular tissues. Drug Metab Dispos (2012) 0.80

Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes. Pharm Res (2004) 0.80

The safety, pharmacokinetics, and efficacy of intraocular celecoxib. Invest Ophthalmol Vis Sci (2014) 0.79

LEDGF(1-326) decreases P23H and wild type rhodopsin aggregates and P23H rhodopsin mediated cell damage in human retinal pigment epithelial cells. PLoS One (2011) 0.79

Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage. Microvasc Res (2011) 0.79

Differential expression of LHRH-receptor in bovine nasal tissue and its role in deslorelin delivery. Peptides (2008) 0.79

Brain mitochondrial drug delivery: influence of drug physicochemical properties. Pharm Res (2011) 0.79

Gene delivery nanoparticles fabricated by supercritical fluid extraction of emulsions. Int J Pharm (2009) 0.79

Functionalized nanosystems for targeted mitochondrial delivery. Mitochondrion (2011) 0.78

Intratracheal budesonide-poly(lactide-co-glycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo(a)pyrene-fed mouse model. J Pharm Pharmacol (2005) 0.78

Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor. J Pharm Pharmacol (2004) 0.77

Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. J Control Release (2013) 0.77

Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye. J Ocul Pharmacol Ther (2012) 0.77

Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol. Curr Pharm Biotechnol (2011) 0.76

pH shift assembly of adenoviral serotype 5 capsid protein nanosystems for enhanced delivery of nanoparticles, proteins and nucleic acids. J Control Release (2013) 0.76

Retracted Hypoxia alters ocular drug transporter expression and activity in rat and calf models: implications for drug delivery. Mol Pharm (2013) 0.76

Pigmented-MDCK (P-MDCK) cell line with tunable melanin expression: an in vitro model for the outer blood-retinal barrier. Mol Pharm (2012) 0.76

Transporter targeted gatifloxacin prodrugs: synthesis, permeability, and topical ocular delivery. Mol Pharm (2012) 0.76

Retracted Hydrophilic prodrug approach for reduced pigment binding and enhanced transscleral retinal delivery of celecoxib. Mol Pharm (2012) 0.76

Potential drug delivery approaches for XFS-associated and XFS-associated glaucoma. J Glaucoma (2014) 0.76

Biosynthesis, characterization, and efficacy in retinal degenerative diseases of lens epithelium-derived growth factor fragment (LEDGF1-326), a novel therapeutic protein. J Biol Chem (2013) 0.75